As General Manager of Tissue Genesis, Ben Chlebina manages the operational, strategic planning, financial and marketing efforts of the Tissue Genesis management to optimize growth and maximize value.
Passionate about regenerative medicine and translational research, Mr. Chlebina joined HHIG with a career focused on biomedical research and drug development. His experience ranges from initial disease assessment and symptom analysis, to in vitro and pre-clinical lab research as well as in-man clinical trials. As a Research Engineer at the Cleveland Clinic, Lerner Research Institute, Mr. Chlebina worked on Parkinson’s disease symptom analysis and control. Working as a Research Scientist for early stage drug development companies, NovelMed Therapeutics and later Juventas Therapeutics, he took part in in vitro research and preclinical animal studies for monoclonal antibody and gene therapies, including cell-based potency assay development. Additionally, as Project Manager, he helped manage biologic drug manufacturing, quality and stability testing, and the coordination of drug product shipments as well as inventory for clinical trials.
Mr. Chlebina received his Bachelor of Science in Biomedical Engineering from Case Western University, his Master of Science in Biomedical Engineering from Duke University, and a Master of Business Administration (MBA) from Carnegie Mellon University, Tepper School of Business.